No Alzheimer’s Drug for Old Men?

New evidence of effectiveness is cause to drop a Biden restriction on Medicare coverage for anti-amyloid treatments

WSJ editorial. Excerpts:

"Two studies presented at the Alzheimer’s Association International Conference last week show that the benefits of amyloid-clearing monoclonal antibodies by Eli Lilly and Biogen-Eisai grow over time. The drugs slowed cognitive decline in clinical trials used for Food and Drug Administration approval by some 25% to 36% over 18 months. In follow-up studies, these benefits doubled at three years for Lilly’s treatment and roughly quadrupled over four years for Biogen-Eisai’s. That’s great news for patients."

"the Biden Centers for Medicare and Medicaid Services (CMS) in 2022 restricted access to all anti-amyloid drugs approved by the FDA because it wasn’t convinced they were “reasonable and necessary.”"